Skip to main content
Elsevier
View Cart
openUserAccount

Books in Drug discovery

Elsevier's Drug Delivery collection is an indispensable resource for scientists and researchers in the pharmaceutical field, exploring the administration of pharmaceutical compounds for therapeutic effects from molecule identification to medication development. It provides comprehensive coverage, including crucial aspects such as drug screening, medicinal chemistry, and preclinical safety assessments. Highlighting emerging trends like precision medicine, AI applications, immunotherapy, and innovative delivery systems, the collection offers insights into the latest advancements and their impact on healthcare.

BooksJournals
31-40 of 44 results in All results

Pharmacology

  • 1st Edition
  • June 19, 2009
  • Miles Hacker + 2 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 6 9 5 2 1 - 5
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 1 9 2 2 - 5
Pharmacology meets the rapidly emerging needs of programs training pharmacologic scientists seeking careers in basic research and drug discovery rather than such applied fields as pharmacy and medicine. While the market is crowded with many clinical and therapeutic pharmacology textbooks, the field of pharmacology is booming with the prospects of discovering new drugs, and virtually no extant textbook meets this need at the student level. The market is so bereft of such approaches that many pharmaceutical companies will adopt Hacker et al. to help train new drug researchers. The boom in pharmacology is driven by the recent decryption of the human genome and enormous progress in controlling genes and synthesizing proteins, making new and even custom drug design possible. This book makes use of these discoveries in presenting its topics, moving logically from drug receptors to the target molecules drug researchers seek, covering such modern topics along the way as side effects, drug resistance, pharmacogenomics, and even nutriceuticals, one in a string of culminating chapters on the drug discovery process. The book is aimed at advanced undergraduates and beginning graduate students in medical, pharmacy, and graduate schools looking for a solid introduction to the basic science of pharmacology and envisioning careers in drug research.

Animal and Translational Models for CNS Drug Discovery

  • 1st Edition
  • November 27, 2008
  • Robert A. McArthur + 1 more
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 4 1 - 2
Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

  • 1st Edition
  • October 6, 2008
  • Robert A. McArthur + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 3 8 5 6 - 1
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 3 9 - 9
Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually.

Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

  • 1st Edition
  • October 6, 2008
  • Robert A. McArthur + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 3 7 3 8 6 0 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 2 0 4 0 - 5
Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

Advances in Cancer Research

  • 1st Edition
  • Volume 96
  • December 19, 2006
  • George F. Vande Woude + 3 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 0 0 6 6 9 6 - 4
  • eBook
    9 7 8 - 0 - 0 8 - 0 4 7 1 0 1 - 3
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.

Target Validation in Drug Discovery

  • 1st Edition
  • September 22, 2006
  • Brian W. Metcalf + 1 more
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 4 6 5 9 7 - 5
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Drug Discovery

  • 1st Edition
  • December 15, 2005
  • Tamas Bartfai + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 3 6 9 5 3 3 - 8
  • eBook
    9 7 8 - 0 - 0 8 - 0 9 1 9 2 3 - 2
Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

Ethnomedicine and Drug Discovery

  • 1st Edition
  • Volume 1
  • March 1, 2002
  • M.M. Iwu + 1 more
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 5 3 1 2 5 - 0
The emergence of new infectious, chronic and drug resistant diseases have prompted scientists to look towards medicinal plants as agents for treatment and prevention. This book provides an interphase between ethnomedical and ethnobotanical approaches to new drug discovery and advances in biotechnology and molecular science that has made it increasingly feasible to transform traditional medicines into modern drugs. These novel approaches also raise new issues and the volume explores economic, ethical and policy considerations of drug development based on indigenous knowledge or traditional medicine.This work also features standardization and development of phytomedicines for major therapeutic indications, including emerging infectious diseases affecting developing and developed countries.The publication provides state-of-the-art information on the most innovative science, the research, the industry, the market, and the future of ethnomedicine and drug discovery.

Trends in Drug Research III

  • 1st Edition
  • Volume 32
  • January 25, 2002
  • H. van der Goot
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 5 4 3 2 3 - 9
The tradition of setting new trends in medicinal chemistry continued at the 13th Symposium where topics included chemical and biological diversity, new paradigms in drug action, and new insights in receptor mechanisms. Other topics of great interest discussed, and included in these proceedings, are the discoveries in green chemistry, the interface between organic synthesis and biosynthesis, the growing problem of resistant micro-organisms and the possibilities to identify new, and better, antibiotics. And finally, in recent developments, the discovery of small molecules with insulin sensitizing properties.

Drug Discovery and Design

  • 1st Edition
  • Volume 56
  • April 18, 2001
  • Frederic M. Richards + 3 more
  • English
  • eBook
    9 7 8 - 0 - 0 8 - 0 4 9 3 3 8 - 1
Strategies to reduce medical uncertainty and build evidence have become critical to the advancement of medical knowledge and modern medical practice. As new techniques and strategies have arisen, so has the need for a current reference work. Drug Discovery and Design examines the latest research in the development of these new strategies. Some of the topics covered include angiotensin converting enzyme inhibitors, HIV protease inhibitors, PPAR agonists for diabetes, and glucan synthase antifungal agents.